Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Suppression of abnormal karyotype predicts superior survival in multiple myeloma

Leukemia volume 22, pages 850–855 (2008)Cite this article

Abstract

Cytogenetic studies were performed as part of all diagnostic and surveillance bone marrow examinations in 956 newly diagnosed patients with multiple myeloma (MM) receiving total therapy (TT) protocols and in 1085 previously treated patients enrolled in non-TT protocols. In both groups, cytogenetic abnormalities (CA) were present in one-third at baseline and persisted in 14% prior to first and 10% prior to second transplant (TT, 5%; non-TT, 15%); post-transplant detection rates increased progressively with time, from 7% within 6 months to 21% within 24 months to 28% at relapse. According to multivariate analyses, overall survival was adversely affected by the presence of CA at baseline (hazard ratio (HR)=7.20, P<0.001) and the development of CA both prior to (HR=3.28, P<0.001) and after first transplant (HR=6.24, P<0.001), whereas suppression of CA pretransplant was favorable (HR=0.38, P<0.001). The presence of CA at relapse further distinguished patients with a short median post-relapse survival of only 11 versus 47 months in those without CA (P<0.0001). Post-relapse survival was independently adversely affected by the detection of CA both at baseline (HR=1.35, P=0.044) and relapse (HR=2.47, P<0.001). Collectively, these results underscore the importance of monitoring for CA and attest to the favorable prognostic consequences of CA suppression with effective therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B . Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453–456.

    CAS  PubMed  Google Scholar 

  2. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.

    CAS  PubMed  Google Scholar 

  3. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659–2666.

    Article  CAS  PubMed  Google Scholar 

  4. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101: 189–195.

    Article  CAS  PubMed  Google Scholar 

  5. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A et al. Predicting long-term (⩾5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211–217.

    Article  PubMed  Google Scholar 

  6. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122: 430–440.

    Article  PubMed  Google Scholar 

  7. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  8. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of MM: a workshop report. Cancer Res 2004; 64: 1546–1558.

    Article  CAS  PubMed  Google Scholar 

  9. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with Total Therapy I; interpretation in the context of global gene expression. Blood 2003; 101: 3849–3856.

    Article  CAS  PubMed  Google Scholar 

  10. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L . Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 1985; 76: 765–769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995; 55: 3854–3859.

    CAS  PubMed  Google Scholar 

  12. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A Sawyer J et al. High incidence of chromosome 13 deletions in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96: 1505–1511.

    CAS  PubMed  Google Scholar 

  13. Shaughnessy Jr J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44–52.

    Article  PubMed  Google Scholar 

  14. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S Colla S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.

    Article  CAS  PubMed  Google Scholar 

  16. Shaughnessy Jr JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol 2007; 137: 530–536.

    Article  CAS  PubMed  Google Scholar 

  17. Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073–7079.

    Article  CAS  PubMed  Google Scholar 

  18. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 133: 430–440.

    Article  Google Scholar 

  19. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  20. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  21. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164.

    Article  PubMed  Google Scholar 

  22. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  23. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827–832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185.

    Article  CAS  PubMed  Google Scholar 

  25. Pineda M, Zangari M, Haessler J, Anaissie E, Tricot J, van Rhee F et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (in press).

  26. Pineda M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F et al. The Arkansas experience since 1989 in 3077 patients. Cancer (in press).

  27. Sawyer J, Waldron J, Jagannath S, Barlogie B . Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41–49.

    Article  CAS  PubMed  Google Scholar 

  28. Kaplan EL, Meier P . Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  29. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

    CAS  PubMed  Google Scholar 

  30. Cox DR . Regression models and life-tables (with discussion). J Royal Stat Soc, Series B 1972; 34: 187–220.

    Google Scholar 

  31. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by CA55819 from the National Cancer Institute, Bethesda, MD, USA.

Author information

Authors and Affiliations

  1. Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    V Arzoumanian, J Sawyer, F van Rhee, C Bailey, J Gurley, J D Shaughnessy Jr, E Anaissie & B Barlogie

  2. Cancer Research and Biostatistics, Seattle, WA, USA

    A Hoering & J Crowley

Authors
  1. V Arzoumanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Hoering
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Sawyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F van Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Gurley
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J D Shaughnessy Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Anaissie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Crowley
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Barlogie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Barlogie.

Additional information

Author contributions: BB and JS designed the study; VA and BB wrote the paper; JS performed and supervised cytogenetic analyses; CB and JG collected data into myeloma database; VA, FvR, EA and BB treated patients on protocols and AH and JC performed statistical analyses.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arzoumanian, V., Hoering, A., Sawyer, J. et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 22, 850–855 (2008). https://doi.org/10.1038/sj.leu.2405091

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405091

Keywords

This article is cited by

Search

Advanced search

Quick links